940 related articles for article (PubMed ID: 22659218)
1. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
2. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study.
Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX
Virol J; 2011 Sep; 8():444. PubMed ID: 21936898
[TBL] [Abstract][Full Text] [Related]
3. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
4. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
5. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir.
Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW
Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931
[TBL] [Abstract][Full Text] [Related]
6. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients.
Moucari R; Boyer N; Ripault MP; Castelnau C; Mackiewicz V; Dauvergne A; Valla D; Vidaud M; Chanoine MH; Marcellin P
J Viral Hepat; 2011 Aug; 18(8):580-6. PubMed ID: 20487260
[TBL] [Abstract][Full Text] [Related]
10. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy.
Barone M; Iannone A; Di Leo A
World J Gastroenterol; 2014 Jul; 20(26):8722-5. PubMed ID: 25024631
[TBL] [Abstract][Full Text] [Related]
11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
[TBL] [Abstract][Full Text] [Related]
12. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B.
Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A
Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368
[TBL] [Abstract][Full Text] [Related]
13. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW
J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898
[TBL] [Abstract][Full Text] [Related]
14. Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response.
Gara N; Tana MM; Kattapuram M; Auh S; Sullivan L; Fryzek N; Walter M; Umarova R; Zhao X; Cloherty G; Doo E; Heller T; Liang TJ; Ghany MG
Hepatol Commun; 2021 Nov; 5(11):1888-1900. PubMed ID: 34558806
[TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
17. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
[TBL] [Abstract][Full Text] [Related]
18. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
19. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
[TBL] [Abstract][Full Text] [Related]
20. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B.
Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF
J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
